As a class of drugs to treat high cholesterol, PCSK9 inhibitors have had trouble gaining tracking in the marketplace.

Michigan-based Esperion on Oct. 18 announced a plan to reduce the company’s overall workforce by 40 percent and significantly decrease operational expenses in fiscal years 2021 and 2022 to optimize long-term growth.

Novartis AG said on Sept. 1 the company agreed on a deal with Britain’s healthcare service provider for use of the drugmaker’s new anti-cholesterol product Leqvio, after the country’s healthcare cost agency NICE approved the medicine.

Novartis will manufacture the anti-cholesterol medicine Leqvio at the company’s own plant in Austria to supply the United States as the Swiss drugmaker seeks U.S. approval that has been delayed by regulatory concerns over a contractor’s Italian facility.

Speculation regarding poorer outcomes for those with high cholesterol and/or heart disease infected with SARS-CoV-2 are well known. A real-world study published by the FH Foundation confirms Covid-19 increased heart attack rates significantly in patients with these conditions. 

Amryt inked an all-stock acquisition deal with Chiasma. The combined company will focus on rare and orphan diseases with three marketed products and a strong development pipeline.

Novartis said on Tuesday that a large British study of the Swiss drugmaker’s cholesterol-lowering medicine Leqvio is not expected to be completed until 2026, a year later than expected, as Covid-19 infections made participant recruitment difficult.

In a long-running court battle over PCSK9 antibodies, Amgen lost the company’s bid to uphold patent claims for the cholesterol drug Repatha against rival drug Praluent, developed by Sanofi and Regeneron.

BioSpace reviewed the top 10 novel drug approvals of 2020, loosely based on projected earnings in the upcoming years.

AstraZeneca is selling European rights (excluding Spain and the UK) to the erstwhile blockbuster cholesterol drug Crestor to German pharmaceutical company Grünenthal as the British drugmaker focuses on cancer treatments.